Cargando…

Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth

PURPOSE: To determine the efficacy of a potassium-competitive acid blocker (P-CAB)-based first-line eradication therapy with bismuth compared with that of proton pump inhibitor-based first-line therapy with bismuth. MATERIALS AND METHODS: Eradication-naive H. pylori-infected patients were consecutiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Ji Yeon, Lee, Sun-Young, Kim, Hyobin, Kim, Jeong Hwan, Sung, In-Kyung, Park, Hyung Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298865/ https://www.ncbi.nlm.nih.gov/pubmed/34296548 http://dx.doi.org/10.3349/ymj.2021.62.8.708

Ejemplares similares

Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection
por: Kim, Tae Ho
Publicado: (2023)

Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
por: Yamada, Shinya, et al.
Publicado: (2016)

Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?
por: Sue, Soichiro, et al.
Publicado: (2021)

Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy
por: Moon, Sang-Gon, et al.
Publicado: (2022)

Seven-day triple therapy is sufficient to eradicate infection caused by Helicobacter pylori without 23S rRNA point mutation
por: Lee, Jung Wook, et al.
Publicado: (2021)

Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication
por: Yoon, Jai Hoon, et al.
Publicado: (2012)

Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
por: Kim, Sung Eun, et al.
Publicado: (2017)

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth
por: Niu, Zhan-Yue, et al.
Publicado: (2021)

Effects of 14-days bismuth- and tetracycline-containing quadruple therapy with concomitant regimen for the first line Helicobacter pylori eradication
por: Kazemi Veysari, Arash, et al.
Publicado: (2023)

Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials
por: Zhang, Mengran, et al.
Publicado: (2022)

Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial
por: Choi, Youn I, et al.
Publicado: (2019)

Seven-day genotypic resistance-guided triple Helicobacter pylori eradication therapy can be highly effective
por: Papastergiou, Vasilios, et al.
Publicado: (2018)

Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection
por: Lee, Seong tae, et al.
Publicado: (2015)

Effect of licorice versus bismuth on eradication of Helicobacter pylori in patients with peptic ulcer disease
por: Momeni, Ali, et al.
Publicado: (2014)

The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication
por: Arj, Abbas, et al.
Publicado: (2020)

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022)

Short-Duration Furazolidone Therapy in Combination with Amoxicillin, Bismuth Subcitrate, and Omeprazole for Eradication of Helicobacter pylori
por: Hasan, Salman R., et al.
Publicado: (2010)

Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia
por: Alsohaibani, Fahad, et al.
Publicado: (2020)

Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori
por: Wang, Junxian, et al.
Publicado: (2021)

The efficacy and safety of furazolidone-bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotic supplementation
por: Noorbakhsh, Nafeh, et al.
Publicado: (2022)

Suppression of Helicobacter pylori Infection With Bismuth Subsalicylate: Was It the Bismuth or the Salicylate?
por: Kunin, Calvin M
Publicado: (2022)

Levofloxacin-Amoxicillin/Clavulanate-Rabeprazole versus a Standard Seven-Day Triple Therapy for Eradication of Helicobacter pylori Infection
por: Chen, Ming-Cheh, et al.
Publicado: (2014)

Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease
por: Shinzaki, Shinichiro, et al.
Publicado: (2018)

Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection
por: Kim, Jeemyoung, et al.
Publicado: (2022)

Effect of Helicobacter pylori Eradication on Functional Dyspepsia
por: Kim, Sung Eun, et al.
Publicado: (2013)

Efficacy of Clarithromycin Containing Bismuth–Based Regimen as a Second-Line Therapy in Helicobacter Pylori Eradication
por: Mokhtare, Marjan, et al.
Publicado: (2015)

Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin
por: Song, Zhiqiang, et al.
Publicado: (2019)

Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
por: Wu, Meng-Chieh, et al.
Publicado: (2017)

Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy
por: Sun, Yingchao, et al.
Publicado: (2022)

A Simplified Low-Dose 10-Day Quadruple Therapy with a Galenic Formulation of Bismuth Salicylate Is Highly Effective for Helicobacter pylori Eradication
por: Dore, Maria Pina, et al.
Publicado: (2023)

The Influence of Past Metronidazole Exposure on the Outcome of Helicobacter pylori Eradication
por: Choe, Younghee, et al.
Publicado: (2022)

Second-Line Bismuth-Containing Quadruple Therapy for Helicobacter pylori Infection: A 12-Year Study of Annual Eradication Rates
por: Shin, Kiwon, et al.
Publicado: (2021)

Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori?
por: Kim, Young Min, et al.
Publicado: (2020)

Helicobacter pylori: Eradication or Preservation
por: Sachs, George, et al.
Publicado: (2012)

Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of Helicobacter pylori
por: Li, Lei, et al.
Publicado: (2018)

Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial
por: Kim, Tae Ho, et al.
Publicado: (2020)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
por: Lee, Ju Yup, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l8jf5uctfpk2am5ddtiukprqu5